Tildrakizumab linked to improvement of HRQOL in psoriasis in a real setting
According to a new study published in The journal of dermatological treatment. The anti-interleukin-23 monoclonal antibody p19 is approved for the treatment of adults with moderate to severe plaque psoriasis. …
Tildrakizumab linked to improvement of HRQOL in psoriasis in a real setting Read More